Literature DB >> 8298817

Vascular and anti-platelet actions of 1,2- and 1,3-glyceryl dinitrate.

D Salvemini1, A Pistelli, E Anggard.   

Abstract

1. The aim of this study was to investigate whether two metabolites of glyceryl trinitrate (GTN), 1,2 and 1,3-glyceryl dinitrate (1,2-GDN and 1,3-GDN) could account for the pharmacological effects of GTN. To this end the formation of nitric oxide (NO) from 1,2- and 1,3-GDN in the presence of bovine aortic smooth muscle cells (SMC) or endothelial cells (EC) was studied. The effects of various thiols on NO formation from these dinitrates was also evaluated. 2. 1,2-GDN or 1,3-GDN (10(-10)-10(-5) M) caused a dose-dependent relaxation of rabbit aortic strips denuded of endothelium and precontracted with phenylephrine. The dinitrates were less than one tenth as potent as GTN. 3. Incubation of 1,2-GDN or 1,3-GDN (75-2400 microM) with SMC for 30 min led to a concentration-dependent increase in nitrite (NO2-) formation but this increase was less than that produced from GTN. Likewise incubation of 1,2-GDN or 1,3-GDN with N-acetylcysteine (NAC), glutathione (GSH) or thiosalicylic acid (TSA) (all at 1 mM) for 30 min at 37 degrees C produced a concentration-dependent increase in NO2- formation. 4. Platelet aggregation induced by thrombin (40 mu ml-1) was not modified by high concentrations of 1,2-GDN or 1,3-GDN (175-700 microM). However, aggregation was inhibited when platelets were exposed to 1,2-GDN or 1,3-GDN (700 microM) in the presence of SMC (0.24-1.92 x 10(5) cells) or EC (0.8-3.2 x 10(5) cells). These effects were abrogated by co-incubation with oxyhaemoglobin (OxyHb, 10 microM) indicating that they were due to NO release. The concentrations of the dinitrates required to inhibit platelet aggregation by 50% were about 15 times higher than for GTN in the presence of the same numbers of SMC or EC.5. When NAC or TSA (both at 0.5 mM) were co-incubated with platelets for 3 min in the presence of1,2-GDN or 1,3-GDN, a concentration-dependent inhibition of platelet aggregation was observed. These anti-platelet effects were abolished by co-incubation with OxyHb (10 microM). Glutathione had no potentiating effects.6. Thus the dinitrate metabolites of GTN are metabolized to NO by SMC or EC and are acted upon by thiols to form NO at concentrations about 10 times higher than those of GTN. In vivo, after oral or intravenous GTN, GDN levels are reached which are more than 10 times higher than those of GTN.These data support the notion that part of the effects of GTN are due to the generation of NO from 1,2-GDN and 1,3-GDN by the cells of the vascular wall.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298817      PMCID: PMC2175832          DOI: 10.1111/j.1476-5381.1993.tb13903.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  THE AGGREGATION OF BLOOD PLATELETS.

Authors:  G V BORN; M J CROSS
Journal:  J Physiol       Date:  1963-08       Impact factor: 5.182

2.  Biotransformation of organic nitrate esters in vitro by human liver, kidney, intestine, and blood serum.

Authors:  F A Posadas del Rio; F Jaramillo Juárez; R Camacho García
Journal:  Drug Metab Dispos       Date:  1988 May-Jun       Impact factor: 3.922

3.  Relationship between glutathione-dependent dentration and the vasodilator effectiveness of organic nitrates.

Authors:  P Needleman; D J Blehm; K S Rotskoff
Journal:  J Pharmacol Exp Ther       Date:  1969-02       Impact factor: 4.030

4.  Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.

Authors:  L J Ignarro; H Lippton; J C Edwards; W H Baricos; A L Hyman; P J Kadowitz; C A Gruetter
Journal:  J Pharmacol Exp Ther       Date:  1981-09       Impact factor: 4.030

5.  An improved method for washing of human platelets with prostacyclin.

Authors:  M Radomski; S Moncada
Journal:  Thromb Res       Date:  1983-05-15       Impact factor: 3.944

6.  Circulatory effects of sublingual and oral sustained-release nitroglycerin in healthy young men.

Authors:  G Nyberg; H Westling
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

7.  Antagonism of glycerol trinitrate activity by an inhibitor of glutathione S-transferase.

Authors:  R A Yeates; M Schmid; M Leitold
Journal:  Biochem Pharmacol       Date:  1989-06-01       Impact factor: 5.858

8.  Nitric oxide formation during microsomal hepatic denitration of glyceryl trinitrate: involvement of cytochrome P-450.

Authors:  D Servent; M Delaforge; C Ducrocq; D Mansuy; M Lenfant
Journal:  Biochem Biophys Res Commun       Date:  1989-09-29       Impact factor: 3.575

9.  Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor.

Authors:  D Salvemini; G de Nucci; R J Gryglewski; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

10.  Kinetic mechanisms for the concentration dependency of in vitro degradation of nitroglycerin and glyceryl dinitrates in human blood: metabolite inhibition or cosubstrate depletion?

Authors:  S Chong; H L Fung
Journal:  J Pharm Sci       Date:  1989-04       Impact factor: 3.534

View more
  2 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its metabolites.

Authors:  Satoru Hashimoto; Atsuko Kobayashi
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.

Authors:  Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme; Pan Pantziarka
Journal:  Ecancermedicalscience       Date:  2015-08-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.